减重国际标准来了！WHO发布首个司美格鲁肽等GLP-1药物指南

Core Viewpoint - The World Health Organization (WHO) has released the first authoritative guidelines on the use of GLP-1 medications for obesity management, emphasizing that obesity is a chronic disease requiring lifelong management rather than a short-term lifestyle issue [4][7]. Methodology of Guideline Development - Since 2009, WHO has upgraded its guideline development process to ensure scientific rigor and transparency, utilizing the GRADE methodology to assess not only efficacy evidence but also patient values, feasibility, cost, and equity [6]. Definition of Obesity - WHO defines obesity as a chronic disease that requires lifelong management, which includes systematic screening, early diagnosis, and continuous management of complications [7]. Core Conclusion 1: Long-term Use of GLP-1 - WHO recommends GLP-1 therapy as a long-term treatment for adult obesity, with "long-term" defined as continuous use for six months or more, opposing the notion of using GLP-1 as a short-term weight loss tool [8]. Core Conclusion 2: Integration with Behavioral Interventions - WHO emphasizes that GLP-1 therapy should not be used in isolation but should be combined with Intensive Behavioral Therapy (IBT) as a key component of treatment, which includes structured exercise, dietary goal setting, and regular consultations [10]. Research Gaps and Future Directions - The guideline identifies key research priorities for future updates, including the long-term effects of GLP-1 on kidney disease, cognitive function, and quality of life, as well as cost-effectiveness across different healthcare systems [11]. Conclusion - The significance of the WHO guidelines lies in establishing a framework for obesity management that prioritizes long-term, sustainable, and equitable care rather than short-term weight loss, marking the inclusion of GLP-1 in global public health discussions [11].